Detection of Germline Variants in Patients With Localized and Metastatic Prostate Cancer Through Guideline-Based Testing.
Document Type
Article
Publication Date
1-2025
Publication Title
Urol Pract
Abstract
INTRODUCTION: There is increasing awareness that patients with prostate cancer frequently harbor germline variants that may carry important implications for them and their family members. Given the variable clinical guidelines, there remains a need to better understand which patients with prostate cancer are likely to harbor pathogenic or likely pathogenic (P/LP) germline variants. We sought to understand factors associated with P/LP germline variants in patients with metastatic or localized prostate cancer qualifying for National Comprehensive Cancer Network genetic testing criteria.
METHODS: Patients diagnosed with prostate cancer were offered genetic testing in accordance with National Comprehensive Cancer Network guidelines. Patient-level factors, including demographic, clinical, and pathologic data, were tracked in a prospectively collected registry. The association of the presence of a P/LP variant in germline testing results with patient-level factors was assessed using univariate and multivariate logistic regression. Variables were tested for overall significance with χ
RESULTS: Five hundred five patients underwent germline testing and had clinical data available. Rates of P/LP germline variants were 7.6% (20/264) in patients with metastatic disease and 11.2% (27/241) in patients with localized disease. The most prevalent P/LP variants were
CONCLUSIONS: In this cohort of patients undergoing guideline-informed germline testing, P/LP germline variants were found in similar proportions across all age ranges and clinical characteristics. Only age at genetic testing for patients with metastatic disease was demonstrated to be predictive of the presence of a P/LP germline variant, highlighting the challenges associated with refining current clinical testing guidelines.
Volume
12
Issue
1
First Page
63
Last Page
72
Recommended Citation
Abusamra SM, Solorzano MA, Quarles J, Luke M, Patel M, Vince R Jr, Jiang R, Volin J, Jacobs MF, Kaffenberger SD, et al. [ Hafron J] Detection of Germline Variants in Patients With Localized and Metastatic Prostate Cancer Through Guideline-Based Testing. Urol Pract. 2025 Jan;12(1):63-72. doi: 10.1097/UPJ.0000000000000727. PMID: 39383006.
DOI
10.1097/UPJ.0000000000000727
ISSN
2352-0787
PubMed ID
39383006